Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Total body weight \>40 kg (88 lb)~* Men and woman age 18-75~* Men and Women must use highly effective methods of contraception for the entirety of the study~Exclusion Criteria:~* History of malignancy within the last 5 years~* Positive for HIV, Hepatitis B or C~* History of tuberculosis~* Diagnosis of non-plaque psoriasis~* Patients with QTcF \>450 msec (males) or \>470 msec (females) at screening~* Live vaccines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ESK-001 Dose Level 1 (Type: EXPERIMENTAL): ESK-001 administered as an oral tablet
- ESK-001 Dose Level 2 (Type: EXPERIMENTAL): ESK-001 administered as an oral tablet
- ESK-001 Dose Level 3 (Type: EXPERIMENTAL): ESK-001 administered as an oral tablet
- ESK-001 Dose Level 4 (Type: EXPERIMENTAL): ESK-001 administered as an oral tablet
- ESK-001 Dose Level 5 (Type: EXPERIMENTAL): ESK-001 administered as an oral tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered as an oral tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).